In this episode, Dr. Richard Pratley, Medical Director at AdventHealth Diabetes Institute, discusses a groundbreaking study on Ozempic. Dr. Pratley shares insights from the global FLOW study, highlighting Ozempic's potential to reduce chronic kidney disease progression, cardiovascular events, and overall mortality in high-risk patients with type 2 diabetes.